Rheumatic Immune-related Adverse Events: Multidisciplinary Perspectives on Recognition and Management

1.50 CME
$0 FEE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Provider Statement: This continuing education activity is provided by Vindico Medical Education.

Support Statement: This activity is supported by an educational grant from Bristol-Myers Squibb.

Target Audience: The intended audience for this activity is rheumatologists, oncologists, and other health care professionals involved in the treatment of patients with irAEs associated with immunotherapies.

Learning Objective: Upon completion of this educational activity, the participant will be better able to:

  • Review the mechanisms of action of immune checkpoint inhibitors as they relate to both an anti-tumor response and the potential for autoimmunity.
  • Assess common irAEs and the role of immunosuppression in management and prevention.
  • Summarize common rheumatic irAEs and strategies for management.
  • Review the importance of collaboration between rheumatologists and medical oncologists for the optimal management of patients undergoing treatment with immune checkpoint inhibitor(s).

Activity Chair:
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Vice Chairman, Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

Laura C. Cappelli, MD, MHS
Assistant Professor of Medicine, Division of Rheumatology
Johns Hopkins University School of Medicine
University of California, San Francisco
Baltimore, MD

Xavier Mariette, MD, PhD
Head of Rheumatology
Bicetre Hospital
Paris-Sud University
Paris, France

Ronald A. Codario, MD

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation:
Vindico Medical Education designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, February 21, 2018 to February 20, 2019.

How to Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the pretest, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.

Activity Chair and Faculty Members reports the following relationship(s):
Leonard H. Calabrese, DO
Consulting Fee: Amgen, GlaxoSmithKline, Horizon, Janssen, Pfizer, Regeneron, Sanofi, UCB
Speakers Bureau: AbbVie, Bristol-Myers Squibb, Crescendo, Genentech, Janssen, UCB

Laura C. Cappelli, MD, MHS
Contracted Research: Bristol-Myers Squibb

Xavier Mariette, MD, PhD
Consulting Fee: Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, UCB
Contracted Research: Biogen, Pfizer, UCB

Reviewer reports the following relationships:
Ronald A. Codario, MD
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2018 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?
Contact us at cme@vindicoCME.com